Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA
August 1, 2016 7:34 AM
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
